TrialCancer2017

Phase 2 study of low-dose clofarabine plus cytarabine for patients with higher-risk myelodysplastic syndrome who have relapsed or are refractory to hypomethylating agents.

Elias Jabbour et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.